Cue Health Past Earnings Performance

Past criteria checks 0/6

Cue Health's earnings have been declining at an average annual rate of -73.7%, while the Medical Equipment industry saw earnings growing at 9.8% annually. Revenues have been growing at an average rate of 1% per year.

Key information

-73.7%

Earnings growth rate

-6.2%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate1.0%
Return on equity-149.2%
Net Margin-526.5%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Take Care Before Jumping Onto Cue Health Inc. (NASDAQ:HLTH) Even Though It's 26% Cheaper

May 10
Take Care Before Jumping Onto Cue Health Inc. (NASDAQ:HLTH) Even Though It's 26% Cheaper

Investors Don't See Light At End Of Cue Health Inc.'s (NASDAQ:HLTH) Tunnel And Push Stock Down 26%

Mar 22
Investors Don't See Light At End Of Cue Health Inc.'s (NASDAQ:HLTH) Tunnel And Push Stock Down 26%

Cue Health Inc.'s (NASDAQ:HLTH) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Jan 28
Cue Health Inc.'s (NASDAQ:HLTH) Price Is Right But Growth Is Lacking After Shares Rocket 31%

We're A Little Worried About Cue Health's (NASDAQ:HLTH) Cash Burn Rate

Jan 06
We're A Little Worried About Cue Health's (NASDAQ:HLTH) Cash Burn Rate

Investors Don't See Light At End Of Cue Health Inc.'s (NASDAQ:HLTH) Tunnel And Push Stock Down 28%

Nov 10
Investors Don't See Light At End Of Cue Health Inc.'s (NASDAQ:HLTH) Tunnel And Push Stock Down 28%

These Analysts Think Cue Health Inc.'s (NASDAQ:HLTH) Sales Are Under Threat

Aug 14
These Analysts Think Cue Health Inc.'s (NASDAQ:HLTH) Sales Are Under Threat

Can Cue Health (NASDAQ:HLTH) Afford To Invest In Growth?

Jul 12
Can Cue Health (NASDAQ:HLTH) Afford To Invest In Growth?

Revenue Downgrade: Here's What Analysts Forecast For Cue Health Inc. (NASDAQ:HLTH)

May 15
Revenue Downgrade: Here's What Analysts Forecast For Cue Health Inc. (NASDAQ:HLTH)

Cue Health Inc. (NASDAQ:HLTH) Analysts Just Slashed This Year's Revenue Estimates By 56%

Mar 21
Cue Health Inc. (NASDAQ:HLTH) Analysts Just Slashed This Year's Revenue Estimates By 56%

We Think Cue Health (NASDAQ:HLTH) Needs To Drive Business Growth Carefully

Mar 12
We Think Cue Health (NASDAQ:HLTH) Needs To Drive Business Growth Carefully

Cue Health Inc.'s (NASDAQ:HLTH) Intrinsic Value Is Potentially 44% Above Its Share Price

Feb 13
Cue Health Inc.'s (NASDAQ:HLTH) Intrinsic Value Is Potentially 44% Above Its Share Price

Cue Health Inc. (NASDAQ:HLTH) Analysts Just Trimmed Their Revenue Forecasts By 24%

Nov 18
Cue Health Inc. (NASDAQ:HLTH) Analysts Just Trimmed Their Revenue Forecasts By 24%

Here's Why We're Not Too Worried About Cue Health's (NASDAQ:HLTH) Cash Burn Situation

Oct 30
Here's Why We're Not Too Worried About Cue Health's (NASDAQ:HLTH) Cash Burn Situation

Cue Health applies for FDA emergency use nod for its flu & COVID-19 molecular test

Oct 04

Cue Health appoints chief medical oficer

Sep 08

Revenue & Expenses Breakdown

How Cue Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:HLTH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2371-373900
30 Sep 23199-2571120
30 Jun 23251-2761330
31 Mar 23329-2911530
31 Dec 22483-1941860
30 Sep 22529-1381920
30 Jun 22683-671870
31 Mar 22733341570
31 Dec 21618331090
30 Sep 21439-11720
30 Jun 21220-24370
31 Mar 2187-37270
31 Dec 2023-47250
31 Dec 197-2160

Quality Earnings: HLTH is currently unprofitable.

Growing Profit Margin: HLTH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HLTH is unprofitable, and losses have increased over the past 5 years at a rate of 73.7% per year.

Accelerating Growth: Unable to compare HLTH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HLTH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.3%).


Return on Equity

High ROE: HLTH has a negative Return on Equity (-149.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/28 23:39
End of Day Share Price 2024/05/28 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cue Health Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Mark MassaroBTIG
Matthew SykesGoldman Sachs